Previous Pharmacy's COVID role continues to expand
Next Steven Bradbury on setbacks and survival

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

2 Comments

  1. Ken Harvey
    24/06/2021

    The Therapeutic Goods Amendment Bill (No. 4) 2000 allowed ‘low-risk’ medicines (mainly complementary medicines labelled AUST L) to be listed automatically in the Australian Register of Therapeutic Goods (ARTG) following self-assessment of regulatory compliance.

    In the second reading debate on this bill, Senator FORSHAW (New South Wales) said, “We do not believe that bills such as this one, which continue the Howard government’s wholesale deregulation of our medicines regulatory processes, either protect public safety or inspire public confidence”.

    Twenty years on, Ben Basger has succinctly summarised the result of a regulatory system that prioritises industry profitability over consumer protection.

    Paul Gibson, CEO of Complementary Medicines Australia, has explained the current regulatory settings, “The industry, the CMA and the TGA work together to promote the appropriate regulation and advancement for our world-class sector, one that supports a growing number of jobs nationally and internationally”. From: https://ajp.com.au/news/keeping-the-standards-high/

  2. Ron Batagol
    25/06/2021

    Great summary by Ben Basger-well referenced and good focus on the de-prescribing issue, including the reference to the study by E.Reeve on. “Deprescribing tools”. Deprescribing is obviously an important issue, if people are solely relying on complementary medicines to the exclusion of conventional medical care, in an environment where you have advertising hype complete with nonsensical but very persuasive celebrity endorsements,. (remind me again- what do singers and dancers know about health issues??).
    Thus, consideration of the need for deprescribing is important for example, in situations such as differentiating between the management of BHP and prostate cancer, which may present with similar symptomatology, or differentiating between childhood fever and the risk of potential progression to meningitis.

Leave a reply